ABSTRACT
BACKGROUND: In the 2016 ESPGHAN recommendations on how to deal with hepatitis E virus infection in immunocompromised children, patients treated with chemotherapy were not specifically mentioned. OBSERVATIONS: Two teenagers treated with chemotherapy for acute leukemia and medulloblastoma, respectively, were diagnosed with hepatic cytolysis. After numerous investigations hepatitis E was found, limiting the good progress of the chemotherapy treatment. CONCLUSION: In the case of liver cytolysis in immunocompromised children treated with chemotherapy, hepatitis E virus infection has to be promptly diagnosed.
Subject(s)
Hepatitis E virus , Hepatitis E , Leukemia , Child , Adolescent , Humans , Hepatitis E/diagnosis , Hepatitis E/drug therapy , Hepatitis E virus/genetics , Immunocompromised HostSubject(s)
Antineoplastic Agents/therapeutic use , Drug Substitution , Leukemia, Myeloid, Chronic-Phase/drug therapy , Protein Kinase Inhibitors/therapeutic use , Adult , Aged , Aged, 80 and over , Drug Resistance, Neoplasm , Female , Follow-Up Studies , Humans , Imatinib Mesylate/therapeutic use , Male , Middle Aged , Retrospective Studies , Survival Analysis , Treatment Outcome , Young AdultABSTRACT
Laboratory detection of spontaneous growth of colony-forming unit-megacaryocytes (CFU-MK), allowing us to distinguish essential thrombocythemia (ET) from reactive thrombocytosis, is therefore useful for the diagnostic of this myeloproliferative disorder. Whether CFU-MK assays allow us to discriminate at least partly between ET and other myeloproliferative disorders such as polycythemia vera (PV) remains, however, to be established. To gain insights about this point, we have performed CFU-MK cultures from bone marrow cells of patients diagnosed with ET (n = 42) or PV (n = 50) using a standardized collagen-based serum-free method. Spontaneous growth of CFU-MK was similarly detected in both 40/42 patients with ET and 47/50 patients with PV. These data suggest clearly that the CFU-MK assay is useful to detect not only ET, but also PV, but fails to discriminate, even partly, between these two myeloproliferative disorders.
Subject(s)
Colony-Forming Units Assay , Megakaryocytes , Polycythemia Vera/diagnosis , Thrombocythemia, Essential/diagnosis , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Polycythemia Vera/blood , Polycythemia Vera/pathology , Predictive Value of Tests , Thrombocythemia, Essential/blood , Thrombocythemia, Essential/physiopathologyABSTRACT
This article presents the French national recommendations for the use of blood products in medicine.
